The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex Pharmaceuticals swung to a profit and logged higher sales in the second quarter, as more people used its cystic-fibrosis drug and the biotechnology company began rolling out new therapies.